Related Experiment Videos
Dextromethorphan for treatment of complex partial seizures
R S Fisher1, B J Cysyk, R P Lesser
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Neurology
|March 1, 1990
Summary
Dextromethorphan (DM) was studied as an add-on therapy for complex partial seizures. While generally safe with negligible side effects, DM did not significantly impact seizure frequency or anticonvulsant drug levels in patients.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Complex partial seizures (CPS) represent a significant neurological challenge.
- Existing antiepileptic drugs (AEDs) may have limitations or side effects.
- Novel therapeutic agents for seizure control are continuously investigated.
Purpose of the Study:
- To evaluate the efficacy and safety of dextromethorphan (DM) as an add-on therapy for severe complex partial seizures.
- To assess the influence of DM on anticonvulsant drug levels and laboratory values.
Main Methods:
- A double-blind, crossover, add-on study design was employed.
- Nine patients with severe complex partial seizures participated.
- Dextromethorphan was administered at a dose of 120 mg/day.
Main Results:
- Dextromethorphan (DM) showed no significant influence on key laboratory values.
- DM did not alter anticonvulsant drug levels in the studied patients.
- A 25% increase in complex partial seizure frequency was observed during DM treatment, which was not deemed clinically significant.
Conclusions:
- Dextromethorphan (DM) appears to be a safe add-on therapy for complex partial seizures with negligible side effects.
- DM did not demonstrate significant efficacy in reducing seizure frequency in this patient cohort.
- Further research may be warranted to explore DM's role in epilepsy management.